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ABSTRACT 
Personal relationships are the key element of many marketing activities for 
creating, developing and maintaining long term business relationships. 
Companies today have focused their attention on creating strong personal 
relationships with partners, suppliers and customers in order to serve their 
interests. The interest is so big that many believe that promotion through 
personal relationships is the new model for marketing (Stewart, 2004). 
Since marketing is partly based on personal relationships, it is very important 
that sales representatives in pharmaceutical companies focus on building such 
relationships. It is of most importance for researchers to evaluate doctor‟s 
perception of medical representatives and the impact of this perception. 
After gathering all information required for understanding the factors that affect 
doctor‟s perception towards pharmaceutical companies, data collection was 
conducted in big urban areas such as Athens, Patra, Heraklion and Ioannina. 
The aim of the research was: To investigate the importance of medical 
representatives as a parameter of company reputation, to demonstrate how 
medical representatives can help to the establishment of a positive company 
reputation, to make useful conclusions which could possibly help a 
pharmaceutical company change and improve its reputation and to evaluate 
doctor‟s opinion for medical representatives. 
After analyzing the findings of the primary research we reached to the following 
conclusions for Medical Representatives as a factor of creating company image in 
the Pharmaceutical Market and to the doctors. 
 For the total of the participating doctors and having as trust as a basic 
criterion, the biggest percentage (about 75%) agreed that indeed they 
trust the Medical Representatives when they visit them 
 In the second level of questions and having as a primary topic Moral 
behavior of Medical Representatives the biggest percentage (76%) of 
participants agreed that the Medical Representatives show moral behavior 
 In the final level of questions that was researched, the usefulness of 
doctors cooperation with Medical Representatives the majority of the 
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doctors (88%) agreed that Medical Representatives are useful partners for 
them, having built at the same time good, interpersonal and business 
relationships with them, (total percent 81%), basing their answers on the 
good visits, total percent of answers 92%   
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CHAPTER 1.INTRODUCTION 
1.1 Introduction 
Personal relationships are the key element of many marketing activities for 
creating, developing and maintaining long term business relationships. 
Companies today have focused their attention on creating strong personal 
relationships with partners, suppliers and customers in order to serve their 
interests. The interest is so big that many believe that promotion through 
personal relationships is the new model for marketing (Stewart, 2004). 
In pharmaceutical companies, medical representatives have the hard 
responsibility of providing credible information to doctors in an environment 
where restrictions are increasing. The number of rules as well as access to 
doctors is becoming even more limited. That is why it is very important for 
medical representatives to promote their image not only to the doctors but also 
to the rest of the staff. 
Although there are many factors that contribute to this, we will focus on the 
following three: 
1. The perception doctors have towards the company for which medical 
representatives work 
2. The perception doctors have for the value of medical representatives as a 
whole 
3. The perception doctors have toward the medical rep himself 
Since marketing is partly based on personal relationships, it is very important 
that sales representatives in pharmaceutical companies focus on building such 
relationships. It is of most importance for researchers to evaluate doctor‟s 
perception of medical representatives and the impact of this perception. 
After gathering all information required for understanding the factors that affect 
doctor‟s perception towards pharmaceutical companies, data collection was 
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conducted in big urban areas such as Athens, Patra, Heraklion and Ioannina. The 
results of this research will present the image perceptions doctors hold for 
paharmaceutical companies in Greece and the role medical representatives play 
in forming the doctor‟s perception. Special attention was given to the elements of 
medical representatives characteristics that doctors consider essential and 
valuable during the calls. The ulterior motive of this assignment is the evaluation 
of the factors that determine a pharmaceutical company‟s reputation. 
A theoretical model was used aiming to depict how a medical‟s rep positive 
image could be created. Pharmaceutical market differentiates from the typical 
market of the other goods especially due to the fact that there is a lack of 
knowledge to the final consumer. The fact that the consumer does not have 
sufficient knowledge as well as no selection choice makes the role of the doctor 
very important, as he is the one who will decide for the customer, based on his 
knowledge and what is best for him (Souliotis et al, 2005). 
Thus, developing and maintaining a positive company image has proven to be a 
hard and complicated procedure that few companies have managed to succeed 
in. A more careful examination of the subject shows that there are internal 
factors that have to be considered from a company in order to outwardly project 
a positive image.  
These factors include what this company represents (personality of the 
company) or what can be seen in its environment (identity of the company). 
Company identity is shown through its communicative marketing. For the 
pharmaceutical market of prescribing drugs, the most important promotional tool 
for many years has been interface selling. Interface selling has been traditionally 
considered to be a face-to-face communication tool that refers to actions 
someone takes through personal intercourse, often by representing a company, 
aiming to inform, convince or remind someone or a group to do things a 
company is after through the representatives (Fill, 1995).  
This research aims to investigate the value of a medical sales team in developing 
a company image and to examine doctor‟s opinion for medical representatives. 
The targets of the present work are: 
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 To make a brief analysis about the environment of the pharmaceutical 
market  
 To proceed to a theoretical approach as complete as possible about the 
company reputation  
 To identify the importance of a positive company reputation in the 
pharmaceutical business today  
 To find information that contributes to building the reputation of 
pharmaceutical companies  
 To present a theoretical model that highlights the factors that build 
company reputation and project a series of assumptions regarding the 
way they influence company reputation 
 To evaluate the importance of interface contact as a tool of 
communicational marketing for the industry 
 To research the relative importance of the medical representatives as a 
factor of company reputation 
 To demonstrate the contribution of the characteristics of the medical 
representatives in building a positive reputation for the company 
 To make useful conclusions which could possibly help a pharmaceutical 
company improve or change its corporate reputation  
 To examine doctor‟s opinion for medical representatives.  
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CHAPTER 2. CONCEPTUAL FRAMEWORK 
 
2.1 Relationship Marketing Introduction 
Relationship Marketing was first defined as a form of marketing developed from 
direct response marketing campaigns which emphasizes customer retention and 
satisfaction, rather than a dominant focus on sales transactions. As a practice, 
Relationship Marketing differs from other forms of marketing in that it recognizes 
the long term value of customer relationships and extends communication 
beyond intrusive advertising and sales promotional messages (Morgan et al, 
1994). With the growth of the internet and mobile platforms, Relationship 
Marketing has continued to evolve and move forward as technology opens more 
collaborative and social communication channels.  
Relationship Marketing is a broadly recognized, widely-implemented strategy for 
managing and nurturing a company‟s interactions with clients and sales 
prospects. It also involves using technology to organize, synchronize business 
processes, (principally sales and marketing activities), and most importantly, 
automate those marketing and communication activities on concrete marketing 
sequences that could run in autopilot, (also known as marketing sequences). The 
overall goals are to find, attract and win new clients, nurture and retain those 
the company already has, entice former clients back into the fold, and reduce the 
costs of marketing and client service. Once simply a label for a category of 
software tools, today, it generally denotes a company-wide business strategy 
embracing all client-facing departments and even beyond. When an 
implementation is effective, people, processes, and technology work in synergy 
to increase profitability, and reduce operational costs (Morgan et al, 1994). 
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2.2  Relationship Marketing  in Pharmaceutical Industry 
 
Salespeople play a key role in the formation of long-term buyer–seller 
relationships, especially in those that have close, interactive, dyadic interfaces. 
As the primary link between the buying and selling firms, salespeople have 
considerable influence on the buyer‟s perceptions of the seller‟s reliability, the 
value of the seller‟s services and, consequently, the buyer‟s interest in continuing 
the relationship (Wright et al, 2004).  In the pharmaceutical industry, sales 
representatives are charged with providing credible product information to 
physicians, in an increasingly constrained environment (ie PhRMA guidelines, 
reduced physician access, increased numbers of sales representatives and so 
on). The end result is that physicians are spending less time with pharmaceutical 
sales representatives (Andaleeb et al, 1996). The outcome of this may be a 
decrease in the perceived value of pharmaceutical sales representatives and an 
increase in the amount of time in which it takes to develop an effective 
relationship marketing strategy. Consequently, it is more important than ever for 
the pharmaceutical sales representative to quickly establish a positive perception 
with the physician and their staff. Although there may be many areas by which 
perceptions are established, for the purpose of this paper, there are three areas 
of primary interest: (1) physician perceptions of the corporation for which the 
representative works; (2) physician perceptions of the pharmaceutical sales 
representative‟s values; and (3) physician perceptions of the personal 
characteristics of the pharmaceutical sales representative. Because relationship 
marketing is one of the primary drivers of sales in the pharmaceutical industry, it 
is imperative that researchers begin to assess physician perceptions of 
pharmaceutical sales representatives and their resulting impact (Wright et al, 
2004). 
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2.3 Promotion in the Pharmaceutical Industry 
 
Traditionally, pharmaceutical companies directed their marketing muscle at 
doctors who have the authority to write prescriptions. This was done primarily 
through the use of pharmaceutical sales representatives, also known as detailers 
or drug reps. In 1998, nearly 65 per cent of total spending was on face-to-face 
selling with office-based physicians, which was conducted by nearly 57,500 
pharmaceutical sales representatives located in the USA. Today, estimates of the 
number of pharmaceutical field sales representatives range as high as 80,000 or 
more (Nelson, 2004). Sales representatives carry information about drugs to 
physicians and are a key factor in whether a drug becomes accepted and 
prescribed. With drugs being continually developed and approved by the Food 
and Drug Administration (FDA), it is virtually impossible for a busy physician to 
keep up-to-date with the drug industry through reading, or from medical 
associates. The pressure on the medical  profession caused by cost containment, 
an ageing population and the „information explosion‟ in the field (Wright et al, 
2004), has curtailed the time available to the physician to keep current with 
medical journals. Physicians rate salespeople to be important sources of 
information, second only to pharmacists. A more recent study, indicated that 
physicians see pharmaceutical sales representatives as an important source of 
information, yet they feel they could gain the required information without the 
representative‟s assistance (Wright et al, 2004). 
Because sales representatives are a significant source of information in an area 
fraught with the potential for harmful consequences, it is important for 
physicians to hold positive perceptions regarding a pharmaceutical sales 
representative‟s drug, company, knowledge, values and so on. These positive 
perceptions are necessary in order for the physician to see the information 
provided as being credible and to have confidence in prescribing the drug.  
The physician‟s most direct point of contact with a pharmaceutical company is 
the pharmaceutical sales representative, many of whom provide these types of 
benefits. It is reasonable, therefore, to expect that the benefits gained from 
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interacting with pharmaceutical sales representatives would translate into 
physicians holding positive perceptions of these representatives. However, any 
negative element in the customer–client (physician–representative) relationship 
lays the groundwork for negative outcomes: refusal, denial, or passive 
aggression. (Wright et al, 2004) 
 
 
2.4 Theoretical model: The Fombrun-Shanley-Stewart model 
 
The Fombrun – Shanley model (1990) comes from an extensive study about 
company reputation that took place in the US and included 292 large enterprises. 
The assessment of a company‟s reputation came from Fortune magazine and 
comprised the points below:  
 The participant‟s evaluations were based on an eleven point scale (0=very 
poor, 10=excellent)  
 The research asked the participants to name companies that had leading 
positions in their branches.  
 Next, research asked the participants to grade these companies based on the 
elements below: 
 Quality of administration  
 Quality of products or services  
 Value of long-term investments  
 Innovation 
 Financial credibility  
 Ability to hire, develop and maintain capable employees  
 Social and environmental politics  
 Use of company assets  
The results supported the general assumption that the public builds the 
reputation of the companies using information about the fundamental status of 
the companies in the enterprise field. More specifically, they use information 
about the logistic status and financial performance of the companies and also 
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information about the participation of institutions or other investors in their 
capital stock that also show their harmonization with the social needs and also 
information about the strategic orientation of the companies.  
It is worth mentioning that the model that is developed for building company 
reputation is based on realistic conditions and situations, where information is 
not complete and also ambiguous. Finally the public does not have homogeny.   
 
 
2.5 Benefits from a positive company reputation 
 
A reputation of a company is its important and valuable asset. A positive one 
may bring many benefits to a company, when a negative one may significantly 
harm it (Milgrom & Roberts, 1986). A company reputation is closely tied up with 
its stakeholders' emotional beliefs about it. Some main issues about company 
reputation are: 
 In a market, companies are exposed to public. On the other hand the 
public depends on the companies reputation in order to reach strategic 
decisions, make career choices or buy products (Dowling, 1986). 
 Company reputation informs the public about how its products, its way of 
function, its strategy and prospective compete with other companies. 
 A positive company image could result in high performance for the 
company by preventing competitor‟s mobility (Caves & Porter, 1977). 
 Positive reputation about the quality of the products of a company allows 
the company to increase prices for its products (Klein & Lefler, 1981; 
Milgrom & Roberts, 1986). 
 To attract capable candidates (Stigler, 1962). 
 To support companies access to the stock market (Beatty & Ritter, 1986) 
 To attract more investors (Milgrom & Roberts, 1986) 
An important aftermath of positive reputation involves the activities between 
companies. The strategic alliances between companies allows them to respond 
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fast and effectively to the changes in the market. These allowances can be found 
from market research to distribution.  
A company with a positive reputation has an increased possibility in regard to 
companies with negative reputation to find allies for strategic reasons (Spekman 
et al, 1996). 
The theory regarding capability to process information states that there are 
certain restrictions in assimilating and processing information during a certain 
time from the human brain (Jacoby et al, 1974). 
People seem to form stable impressions for an object, first by categorizing it and 
at the same time there is a drastic reduction in accepting new information that 
could change this impression. This characteristic of human nature has to do with 
the mental processing of an irritant.  
Having a general impression of an organization, where detailed information is 
forgotten as time goes by and the fact that the public evaluates companies 
according to their reputation may be beneficial for the organization. Also a 
negative factor can be more easily forgotten (Balzer et al, 1992). 
From the moment a general reputation is established for a company then it 
determines the way the public reacts towards this company and more so, 
sometimes this image may last longer than the real image of the company. In 
this way in times of crisis, companies with a positive reputation can handle them 
better and can have better results, while a company with a negative reputation 
in similar situations will have to give more effort and fight more (Caruana, 1997). 
 
2.6 Reputation of pharmaceutical companies and its meaning to the 
sales force 
 
Medical information through calls is the most important channel between 
companies and doctors. Sales teams are considered to be the third most 
important element of a pharmaceutical company and there is a big degree of 
correlation with the company identity through the image of a sales force 
(Stewart, 2004).  
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Residents‟ perceptions toward industry gifts and interactions changed modestly 
during their training to reflect institutional policy. “Appropriate” gifts of minimal 
value were generally perceived as increasingly appropriate, whereas 
inappropriate over time. (Schneider, 2006). In April 2003 the federal government 
issued “Compliance Program Guidance for Pharmaceutical 
Manufacturers”(Chimonas, 2005). Pharmaceutical companies invest large sums 
of money promoting their products. They use a multifaceted approach to drug 
promotion, incorporating techniques such as hospital and office detailing by 
pharmaceutical representatives. 27% accept receive benefits from the 
pharmaceutical industry and that is influential in their own prescriptions. 
(Castresana, 2005). Residents interacted substantially with pharmaceutical 
representatives. The majority of residents found the interactions useful and 
believed their prescribing practices were not influenced (Randall, 2005).  Contact 
with pharmaceutical representatives is common among residents. The majority 
felt that the interactions were appropriate. A minority felt that their own 
prescribing could be influenced by contact or gifts. Resident prescribing was 
associated with pharmaceutical representative visits. A variety of policy and 
educational interventions appear to influence resident attitudes toward 
interactions with industry (Zipkin DA, 2005). Pharmaceutical company 
representatives could influence the prescribing habits and professional behavior 
of physicians (Wofford, 2005). 
Considerable evidence from the social sciences suggests that gifts of negligible 
value can influence the behaviour of the recipient in ways the recipient does not 
always recognize. Policies and guidelines that rely on arbitrary value limits for 
gift-giving or receipt should be re-evaluated (Katz, 2003). 
Controversy exists over the fact that physicians have regular contact with the 
pharmaceutical industry and its sales representatives, who spend a large sum of 
money each year promoting to them by sponsored teachings and symposia. 
Attending sponsored continuing medical education (CME) events and accepting 
funding for travel or lodging for educational symposia were associated with 
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increased prescription rates of the sponsor‟s medication. The extend of 
physician-industry interactions appears to affect prescribing and professional 
behaviour and should be further addressed at the level of policy and education 
(Wazana, 2000). 
Little is known about patients‟ awareness of and attitudes about gifts to 
physicians from pharmaceutical companies. 32,5 percent did not approve of their 
physicians accepting payment by a pharmaceutical company of medical 
conference expenses and from 28,0 percent to 43,4 percent disapproved of their 
physicians attending specific social events sponsored by pharmaceutical 
companies at a medical conference (Blake, 1995). 
There is an effect of three types of interaction between physicians and the 
pharmaceutical industry-company-funded clinical trials, company-sponsored 
continuing medical information (CMD) and information for physicians supplied by 
pharmaceutical detailers-on orientation and quality of clinical trials, content of 
CME courses and physicians‟ prescribing behaviour. Physicians are affected by 
their interactions with the pharmaceutical industry (Lexchin, 1993). 
Pharmaceutical companies in industrialized countries generally view Medical 
Representatives as the most crucial element in the promotion of their products, 
with the result than over 50 percent of expenditures on promotion are devoted 
to Medical Representatives. Studies from a number of industrialized countries 
have shown that over 90 percent of physicians see view Medical Representatives 
and a substantial percentage rely heavily on them as sources of information 
about therapeutics (Lexchin, 1989). 
Factors that influence prescribing decisions are (Schumock, 2004): 
 Safety 
 Effectiveness 
 Formulary status 
 Restrictions on prescribing 
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Factors that were drug-related or what involved policy-related programs tended 
to be more influential than indirect factors. 
According to the doctors the most important sources of influence in their 
professional practice are: attendance at training courses, reading articles and 
reports, implementation of protocols designed by the professionals of the centre 
themselves and discussion with colleagues on how to deal with a given health 
problem. Accordingly, the least important ones are: economic incentives and 
information provided by medical representatives from pharmaceutical companies 
(Fernandez, 2000) 
Some of the largest pharmaceutical companies are classified according to their 
corporate image, the performance of the sales force and their other potential, as 
these are seen from the doctor‟s point of view. 
Therefore extra attention must be given to the enhancement of the elements of 
the sales team, because this can contribute significantly to shaping a positive and 
strong image of a company.  
The Marketing Communications department of a pharmaceutical company has 
some specific goals (Smith, 1991), which can include one or more of company‟s 
levels, like the functional, the SBU or the corporate (Fill, 1995): 
 To make a product known  
 To build an image for the product to the target customers group  
 To transfer information about the value this has to its customers and its 
specific features  
 To be effective against competitive actions 
 To build an intimacy and familiarity for consumers with the packaging and 
the name of the product   
 To show a unique proposal in the prescribers mind that supports the 
specific choice of product  
 To build a positive and strong image for the company 
Company image of a pharmaceutical business can be defined by a variety of 
factors and engage several groups. The development and enhancement of a 
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positive and preferable image for a pharmaceutical company is important for five 
categories-targets (Corstjens, 1991): 
 Prescribers (builds a environment of credibility and trust and acts as a 
mechanism of reducing risks while making decisions regarding prescribing)  
 Stock market (enhances and increases the price of a stock, which is very 
important in case of merge or buying off and appeasing shareholders)  
 Government and regulatory services (for speeding up approval 
procedures)  
 Employees (to improve the devotion of HR and attract the best 
candidates)  
 Groups with special interest (e.g. unions and consumer organizations to 
prevent negative action from them)  
Even though patients are not included in this list, in the past years there is an 
increase in the attention given to patients from pharmaceutical companies, 
especially in the US (Pratley, 1996), where since June 1996 company image is 
promoted through the media, especially television, which targets medical staff, 
stock buyers and the general population. It is a fact that a company with a good 
reputation attracts employees, investors and suppliers. Good reputation 
enhances the value of a company and contributes to building strong bases that 
can guarantee the effective handling of future crisis.  
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Doctor‟s perception for the model of Medical Representatives  
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Source: Wright et al, 2004 
 
 
2.7 The role and significance of medical representatives 
 
Personal sale is traditionally considered to be an interpersonal tool that refers to 
action one makes through interpersonal contact often by representing a 
company and aiming at informing, convincing or reminding a person or a group 
to do beneficial things for the company one works for (Fill, 1995). 
According to the Association of the British Pharmaceutical Industry (ABPI) some 
of them are:  
 To provide additional scientific information for the drugs they promote 
(Ziegler et al, 1995) 
 To work as a link between the company and the doctor by carrying 
importation from one to another  
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 To provide studies for the company products and related issues  
 To organize meetings, not only for promotional causes but also for 
educational  
 To consult doctors for adverse effects  
Medico-Pharmaceutical Forum (1995) characterized medical representatives as 
the basic link between pharmaceutical industry and doctors not only because 
they act as a promotional mean but also because they are the center for a both 
way communication relationship. 
During the visits medical representatives give the doctors detailed information 
about the company products, their characteristics, their composition, indications 
and adverse events as well as the cautions (ABPI August 2004). Doctors accept 
the fact that they contribute to their education as they inform them about recent 
developments and that helps them in their job (Andaleeb and Tallman, 1996). 
The benefits that pharmaceutical companies have are discussed in a publication 
of ABPI (Industry‟s Issues, 1996). Medical representatives work for their 
companies benefit by pointing out the needs, changes in needs and behavior of 
the doctors (Lambert et al, 1990). In fact some researchers think that medical 
representatives can influence the doctors decisions on which drug they will 
prescribe (Beardsley, 1993). 
Medical representatives have a significant role in carrying information before the 
launch of a product, about the trends and doctors needs and the possible 
acceptance a new drug could have. Additionally medical representatives carry 
doctors‟ interest for clinical studies. Clinical studies are particularly important as 
they build a very strong relationship between doctors participating and 
companies (Wells, 1987) and second of all because phase IV proceeds 
(evaluation of the drug after the launch) which is essential for the development 
of each chemical substance (ABPI briefing, 1996). 
The importance of medical representatives can also be seen from the huge 
amounts of money invested in them from pharmaceutical companies. Usually 40-
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50% of the total promotional budget is meant for this issue (Mackowiak et al, 
1985; Marshall, 1994). 
According to Smith (1991), even though the practices are different, usually the 
pharmaceutical companies spend the majority of their promotional expenses in 
medical representatives.  
Riedlinger (1994) says that the average yearly cost in 1994 for training a medical 
representative was about 150.000$ in USA, while Wilson (1990) in data from 
1990 referred to this kind of expenses as investment. In the UK it is estimated 
that the training of a new rep costs about 80.000£ (Bannon, 1997). Moreover, 
the importance of medical reps can also be seen from the increasing hiring 
number.  
To sum up, the value of medical representatives as a selling mean is based on 
the nature of the products, the nature of the industry and also the nature of the 
clients, which for the pharmaceutical industry are the prescribers. 
 
2.8 The medical’s representative value 
 
A medical rep must have excellent knowledge of the competitive products, 
however must never give false information and mislead the doctor. Therefore 
knowledge of products and correct presentation are basic and define honesty, 
which is essential for the health factor.   
 Medical reps that speak honestly have a positive image to doctors.  
Doctors‟ trust for a rep is created in many ways. Generally it means that the 
doctor counts on the rep that he will serve his interests right and long term. 
What is more, trust plays a determinant role in selling.  
Doctors trust for a medical rep can be created in many ways.  
 Medical reps that seem trustworthy have a positive image to doctors.  
Providing accurate information to doctors is very important, as the doctor 
depends also on them to make decisions. The moral rep must not exaggerate, 
hide or change information, especially since such behavior has a negative impact 
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for doctor‟s perception of the rep, his company but also for medical reps in 
general. But also the reputation of a doctor can be influenced if prescribing 
wrong drugs. 
 Medical reps that are moral have a positive image in doctors.  
Honestly, trust and morality are three of the basic reasons that build a positive 
image to the reps and also give them value.  
Based on all the previous data presented, the following hypotheses were 
developed: 
H1: There is a difference between doctors understanding the Medical 
Representatives usefulness 
H2: There is a difference as for the quality of the relationship of the Medical 
Representatives that visit me . 
H3: There is a difference as for the quality of Medical Representative‟s calls 
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CHAPTER 3. RESEARCH DESIGN 
 
3.1Aim of the research 
 
The aim of the research is: 
 To investigate the importance of medical representatives as a parameter 
of company reputation 
 To demonstrate how medical representatives can help to the 
establishment of a positive company reputation 
 To make useful conclusions which could possibly help a pharmaceutical 
company change and improve its reputation  
 To evaluate doctor‟s opinion for medical representatives 
 
3.2 Collecting and analyzing information 
 
Collecting data may take longer than secondary and the procedure is more 
complicated. However its results may be more accurate (Kent, 1995). Data can 
be collected with qualitative and quantitative research. Qualitative research has 
to do with data that are hard to find or acquiring them is hard. Such data may be 
opinions or evaluations which are not countable, mathematic figures (Marshall & 
Rossman, 1994). On the other hand quantitative research is the one that uses 
techniques and samples and gives results that can be statistically evaluated 
(Churchill, 1995). For the causes of this assignment quantitative research was 
used.  
 
3.3 Planning of the research 
 
The questionnaires were personally and face to face since the probability of 
getting responses by doctors is poor given their limited time spent to 
administrative tasks and full focus on their medical practice. Telephone 
interviews would be too impersonal and valuable information might have missed. 
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The logistics of the data collection process requested pre-arranged  
appointments with doctors. Each doctor personally was given specific instructions 
for the completion of the questionnaires.  The aims and objectives of the study 
were explained to doctors prior to their concent in taking part to the study. 
 
3.4    Methods for collecting evidence  
 
For reasons that have to do with cost, time and human limits it is not possible to 
gather information from all doctors who are a part of the medical community. 
Therefore a sample was taken from this population and used a sampling method 
in order to reach conclusions about the contribution of Medical Representatives 
and their role in shaping a company‟s reputation. The steps in planning the 
sample were: 
1. Definition of the population that will participate in the research  
2. Definition of the size of the sample  
3. Definition of the sampling procedure that will better serve the goals of the 
research  
 
3.5    Sampling 
 
The population, as mentioned before, were Psychiatrists, Neurologists (easiest 
access, provide more time for these types of research, involvement with human 
behavaviour) that practice the medical profession in the areas of Athens, Patra, 
Heraklion and Ioannina. 
The selection of specific specialties happened after a research that took place in 
doctors in the area of Athens and especially with 40 key opinion leaders. The 
research was performed with interviews and the question was which specialty of 
doctors they thought was the most indicated to have an opinion for the Medical 
Representatives of pharmaceutical companies active in Greece.  
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The larger the sample, the less the probability for error (Robson, 1997). 
However, due to the limited time and the fact that the research will be 
conducted by only one person (the author), the largest number of doctors that 
could participate is 200.  Out of 200 doctors that were selected, 149 completed 
the questionnaire. (95 men and 54, women). As far as place of work is 
concerned, 72 have private office, 65 work in hospital, 2 in private clinic and 10 
did not answer this question.  
 
The various methods of sampling are divided into those that are based on known 
probability (regular) and those based on unknown probability (where the chance 
of selecting each candidate is not known). Each of these methods can be further 
divided e.g. the not possible samples are classified as convenience, judgmental 
or quota, while the samples with known possibility can be simply random, 
stratified or cluster and some of them can be further divided.  
In regular samples the sample is being extracted representative (cross-section) 
and in not normal samples the personal judgment takes part in selecting it. Since 
the goal of this assignment is to make generalized assumptions on doctor‟s 
perceptions, there is a need to find a method that serves this goal. After thought 
the simple random sampling method was selected. This method is a clear 
method of sampling. Each participant has equal chance of being selected. In this 
case a full catalogue of the participants is required. The major reason for 
selecting this method is the fact that a full list of Psychiatris-Neurologists in the 
selected areas (Athens, Patras, Ioannina and Heraklion) is available.  
 
3.6   Planning of the questionnaire 
 
It is important to note that a significant extent of standardization is given to the 
questionnaire on purpose (Questionnaire is provided in the Appendix). The 
questions were presented with the exact same order to all participants. The 
reason for the high standarisation grade was essential to make sure that all 
participants would answer the same questions. Additionally, the standarised 
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questionnaire was selected because it is easier to use, to process and analyse, 
since it evaluates subjective opinions. The questionnaire was pretested in 5 
people to check whether the language is comprehensive. The pretest of the 
questionnaire resulted in slight changes in the wording of the questions and 
items examined. The 5 completed questionnaires were discarded and were not 
considered in the final analysis. Items and questions used aimed to simplicity and 
clear meaning to ease the respodents‟ completion. Taking into account that the 
introduction of a researcher may influence the acceptance rate of the 
questionnaire and furthermore participants trust and cooperation, the first page 
of the questionnaire was used to explain the study, revealed the researcher‟s 
identity and the study‟s aims and objectives. It was clarified that any answers 
given would be confidential. Also it was stated that the assignment was academic 
and that they would be informed of the results of the research if they requested 
them  
The questionnaire was created to calculate the relative impact of the Medical 
Information Team (Medical Representatives) in building the company image as 
well as doctor‟s perceptions of Medical Representatives. The bases on which the 
questionnaire was structured where: 
 Morality 
 Trust 
 Honesty  
 as described in the Henry Stewart (Stewart 2004) model. Constructs used 
by Doney and Cannon (1997), Lagace, Ingram and Boorom (1999) and 
Ramsey and Sohi (1997) were the sources of the used items and scales. 
Likert scale was used. Its selection was based on its simplicity and 
objectivity while it allowed participants to show their level of agreement or 
disagreement with a series of statements depending on the study topic.  
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3.7   Questions-goals 
 
The goals of the questions featured in the questionnaire are the following: 
 The first group of questions involves the components of Medical 
Representatives, based on the issue of trust and how this is evaluated 
from doctors. The aim of these questions is to locate the parameters 
doctors think are essential so to reach a conclusion about the Medical 
Representatives. An agreement scale from 1 (totally disagree) to 7 (totally 
agree) was used to rank the answers. 
 Questions 1 to 14 request from the participants to evaluate the morality 
behavior of Medical Representatives. The goal is to evaluate each 
parameter separately so to base a valuation on it regarding doctor‟s 
opinion for Medical Representatives and the morality behavior that the 
present. 
 The third group of questions involves the honesty and integrity as part of 
the cooperation of doctors and Medical Representatives.  
The reason for selecting these group of questions was the fact that during 
the last period there have been major changes in the Code of Ethics of 
Pharmaceutical Companies and it is essential to focus on new elements of it 
like morality, trust and honesty, since they are a part of significant evolution 
in the image of Medical Representatives and Pharmaceutical Companies.  
 
To depict the value of the study high quality paper and photocopies were used.  
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CHAPTER 4 FINDINGS 
 
4.1 Findings 
 
Results of primary reserach 
All analysis was conducted using the statistical program SPSS 13 (Statistical 
Package for Social Sciences). This program has the ability to manage a vast 
volume of data and perform complicated calculations.  
Research accuracy 
Accuracy alpha evaluates internal consistency of data in a questionnaire, which 
means if data has the tendency to double count. Accuracy alpha is considered 
acceptable when the contributor alpha is about 70 or more. In our case the 
results of accuracy analysis alpha are noted in the chart bellow:  
 
Item-total Statistics    
     
Scale Scale Corrected     
Mean Variance Item- Alpha   
if Item if Item Total if Item   
Deleted Deleted Correlation Deleted   
          
The Medical Representatives that visit me 
don‟t lie  
16,0671 25,8738 -0,2226 0,7569 
The Medical Representatives that visit me 
are not totally honest when informing me 
17,9396 16,0707 0,4957 0,518 
The Medical Representatives that visit me 
are mostly interested in serving their 
interests  
16,6913 17,3365 0,3697 0,5758 
The Medical Representatives that visit me 
don‟t seem to care about my needs  
18,0805 17,9124 0,4514 0,5454 
My partners don‟t usually trust Medical 
Representatives  
17,9933 14,8175 0,638 0,4497 
The Medical Representatives that visit me 
are usually unreliable  
18,9329 18,2252 0,5098 0,5325 
 24 
 
 
N of Cases = 149 N of Items = 6 
                    
Alpha = 0,6245               
 
 
Item-total Statistics         
            
Scale Scale Corrected     
Mean Variance Item- Squared Alpha  
if Item if Item Total Multiple if Item   
Deleted Deleted Correlation Correlation Deleted   
The Medical Representatives that visit me 
often misrepresent scientific data about drugs  
43,4595 157,461 0,4174 0,2867 0,881 
The Medical Representatives that visit me 
often blame others for their mistakes  
43,6689 148,781 0,6989 0,5496 0,8691 
The Medical Representatives that visit me 
usually don‟t give accurate data about the side 
effects of drugs 
43,0068 148,524 0,6039 0,4133 0,8727 
The Medical Representatives that visit me 
usually take advantage of new and 
inexperienced doctors  
43,5338 145,475 0,6913 0,5415 0,8683 
The Medical Representatives that visit me 
usually don‟t do me favors so to feel obliged 
towards them  
42,3986 169,343 0,0389 0,1437 0,8986 
The Medical Representatives that visit me 
often promote drugs with a likelihood of 
increased side effects  
43,4257 153,144 0,5443 0,3719 0,8756 
The Medical Representatives that visit me 
usually exaggerate when presenting the 
benefits of a new drug 
41,6284 151,541 0,4996 0,4209 0,8778 
The Medical Representatives that visit me 
usually are not completely honest as for the 
sufficiency of quantities of drugs in the market  
43,0405 151,196 0,5211 0,3556 0,8767 
The Medical Representatives that visit me 
usually make bad remarks about their 
43,1351 144,227 0,6755 0,5526 0,8688 
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competition 
The Medical Representatives that visit me 
usually are interested only for their own 
interests and not mine  
42,723 149,372 0,5915 0,4529 0,8733 
The Medical Representatives that visit me 
when asked usually reply even though they 
are not well familiar with the topic  
43,0135 146,027 0,6357 0,5306 0,871 
The Medical Representatives that visit me 
often give misleading information in case their 
competition is present  
43,5676 145,757 0,7417 0,6448 0,8665 
The Medical Representatives that visit me are 
usually pressuring me in order to ensure the 
prescription of their  
42,2905 149,106 0,5578 0,422 0,8749 
The Medical Representatives that visit me 
often make suggestions that contradict to the 
Code of Ethics of pharmaceutical companies  
43,7635 149,774 0,6028 0,5334 0,8728 
Reliability Coefficients 14 items         
                
Alpha = 0,883 Standardized item alpha = 0,8839 
 
 
As we can see from the charts above (which where produced from accuracy 
analysis using statistical package SPSS 13), accuracy alpha in the fist case is 
0,6245 and in the second case 0,883 – these figures are considered acceptable- 
which means that the accuracy of the scale is acceptable.  
 
Variation analysis by one factor 
The analysis of the variation, or as usually called dispersal analysis is one of the 
most common statistical methods. Data experiment usually contains a great 
number of market variations. The variation analysis aims to determine the main 
variation source of a quantitive variable, as the variable amount that‟s due to 
each one of the different variables we are interested in. The rest of data 
variation is believed to be due to accidental factors and that‟s the reason it‟s 
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called error. The simplest version of variation analysis is the analysis by one 
factor, for example we are trying to examine a theory with this form: 
H0 : There is no great difference caused by this factor a or aj = 0 
Oppose to 
H1 : There is a great difference caused by this factor   a or aj≠ 0 
In the following analysis, we„ll show using the Anova through SPSS 13 program if 
there is great difference between the question groups.  
I) First analysis refers to the question: I believe that the officials that provide 
Medical information are my valuable partners. Consequently we would like to 
examine the difference there is between the doctors understanding as far as the 
usefulness of M.R. is concerned. 
H0 : There is no difference between doctors understanding the M.R. usefulness  
Oppose to 
H1 : There is a difference between doctors understanding the M.R. usefulness 
  
First the chart of variation analysis is created through  SPSS 
ANOVA 
 
I consider the Medical Representatives useful partners  
  
   
                Sum 
of  
               
Squares 
        
df 
           
Mean   
         
Square          F 
       
Sig. 
Place of work Between Groups 2,53 7 0,361 0,893 0,514 
  Within Groups 57,107 141 0,405    
  Total 59,638 148     
Area of work Between Groups 4,458 7 0,637 0,933 0,483 
  Within Groups 96,24 141 0,683    
  Total 100,698 148     
Years of practice Between Groups 5,962 7 0,852 1,218 0,297 
  Within Groups 98,588 141 0,699    
  Total 104,55 148     
Practice abroad Between Groups 1,895 7 0,271 1,311 0,249 
  Within Groups 29,111 141 0,206    
  Total 31,007 148     
Age Between Groups 4,294 7 0,613 0,98 0,448 
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  Within Groups 88,283 141 0,626    
  Total 92,577 148     
Gender Between Groups 0,967 7 0,138 0,582 0,77 
  Within Groups 33,463 141 0,237    
  Total 34,43 148       
 
When analyzing the results above, “sig.” is bigger than 0,05 so we accept condition Η0.  
 
 
       
 
ΙΙ) The second analysis refers to the question: Generally speaking how would you 
characterize your relationship with the Medical Representatives that visit you? Therefore 
we want to examine if there is a difference in doctors perception as for the quality of 
their relationship with the Medical Representatives.  
Η0 : There is no difference as for the quality of the relationship of the Medical 
Representatives that visit me  
versus 
Η1 : There is a difference as for the quality of the relationship of the Medical 
Representatives that visit me . 
First the variation analysis chart is produced from SPSS  
 
ANOVA 
Generally speaking how would you characterize your relationship 
with the Medical Representatives that visit you? 
 
  
   
               Sum 
of  
              
Squares     df 
           
Mean  
          
Square     F 
                        
Sig. 
Place of work Between Groups 2,763 6 0,461 1,15 0,337 
  Within Groups 56,874 142 0,401    
  Total 59,638 148     
Area of work Between Groups 3,615 6 0,603 0,881 0,51 
  Within Groups 97,083 142 0,684    
  Total 100,698 148     
Years of practice Between Groups 8,433 6 1,406 2,077 0,06 
  Within Groups 96,117 142 0,677    
  Total 104,55 148     
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Practice abroad Between Groups 1,521 6 0,254 1,221 0,299 
  Within Groups 29,485 142 0,208    
  Total 31,007 148     
Age Between Groups 6,981 6 1,163 1,93 0,08 
  Within Groups 85,596 142 0,603    
  Total 92,577 148     
Gender Between Groups 1,314 6 0,219 0,939 0,469 
  Within Groups 33,115 142 0,233    
  Total 34,43 148       
 
When analyzing the results above, “sig.” is bigger than 0,05 so we accept condition Η0. 
 
ΙΙΙ) The last analysis refers to the question: How would you characterize the calls of 
Medical Representatives? Therefore we want to examine if there is a difference in the 
doctors perception of Medical Representative‟s calls.  
Η0 : There is no difference as for the quality of Medical Representative‟s calls.  
versus 
Η1  : There is a difference as for the quality of Medical Representative‟s calls 
First the variation analysis chart is produced from SPSS 
 
 
ANOVA 
 
How would you characterize the calls of Medical 
Representatives? 
 
 
  
   
               Sum 
of 
               
Squares       df 
         Mean 
         
Square 
            
F 
        
Sig. 
Place of work Between Groups 3,812 6 0,635 1,616 0,147 
  Within Groups 55,826 142 0,393    
  Total 59,638 148     
Area of work Between Groups 4,072 6 0,679 0,997 0,43 
  Within Groups 96,626 142 0,68    
  Total 100,698 148     
Years of practice Between Groups 5,927 6 0,988 1,422 0,21 
  Within Groups 98,623 142 0,695    
  Total 104,55 148     
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Practice abroad Between Groups 1,128 6 0,188 0,893 0,502 
  Within Groups 29,879 142 0,21    
  Total 31,007 148     
Age Between Groups 4,745 6 0,791 1,279 0,271 
  Within Groups 87,832 142 0,619    
  Total 92,577 148     
Gender Between Groups 1,375 6 0,229 0,985 0,438 
  Within Groups 33,054 142 0,233    
 Total 34,43 148       
 
When analyzing the results above, “sig.” is bigger than 0,05 so we accept condition Η0. 
 
The following analysis focuses on doctors’ trust for Medical 
Representatives in relation to the visits.  
 
MR that visit me are usually honest 
1% 
1% 
1% 
4% 
17% 
37% 
32% 
7% 
DK/NA 
Totally disagree 
Disagree 
Rather disagree 
Neither agree or  
disagree 
Rather agree 
Agree 
Totally agree 
 
 
From 149 people asked the majority of the questioned (76% agrees that the 
Medical Representatives that visit them are usually honest).  
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MR that visit me don’t lie 
1,3 2 
6,7 
16,1 
31,5 
34,9 
7,4 
DK/N
A 
Disagree 
Rather disagree 
Neither agree 
or disagree 
Rather agree 
Agree 
Totally agree 
 
From 149 people asked the majority agrees that Medical Representatives don‟t lie 
during the visit. 
 
 
MR that visit me are not totally honest when informing me   
 
3% 
9% 
25% 
23% 
18% 
13% 
8% 
1% 
DK/NA 
Totally agree 
Disagree 
Rather disagree 
Neither agree or 
disagree 
Rather agree 
Agree 
Totally agree 
 
 
From 149 people asked the majority – 57%- does not agree that Medical 
Representatives that visit them are not totally honest when informing them 
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MR that visit me are mostly interested in serving their interests 
 
1% 
3% 
10% 
7% 
30% 
23% 
17% 
9% 
DK/NA 
Totally disagree 
Disagree 
Rather disagree 
Neither agree or 
disagree 
Rather agree 
Agree 
Totally agree 
 
 
From 149 people asked the majority (49%) agreed that Medical Representatives 
are mostly interested in serving their own interests. 
 
 
My partners don’t usually trust MRs 
3% 
11% 
22% 
25% 
20% 
13% 
5% 
1% 
DK/NA 
Totally disagree 
Disagree 
Rather disagree 
Neither disagree or 
agree 
Rather agree 
Agree 
Totally agree 
 
 
From 149 people asked the majority –58%- disagreed with the statement that 
their partners don‟t trust Medical Representatives 
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MR that visit me are usually unreliable 
2% 
27% 
38% 
20% 
9% 
3% 
1% 
DK/NA 
Totally disagree 
Disagree 
Rather disagree 
Neither disagree or 
agree 
Rather agree 
Agree 
 
 
From 149 people asked the majority –85% - disagreed with the statement that 
Medical Representatives are usually unreliable. 
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The following analysis focuses on Medical Representative’s behavior 
when they visit a doctor . 
 
 
MR that visit me often misrepresent scientific data about 
drugs  
11% 
34% 
30% 
11% 
8% 
6% 
Totally disagree 
Disagree 
Rather disagree 
Neither disagree 
or agree 
Rather agree 
Agree 
 
 
From 149 people asked the majority –75% - disagreed with the statement that 
the Medical Representatives that visit them often misrepresent and change 
scientific data about pharmaceutical drugs. 
 
 
MR that visit me often blame others for their mistakes 
 
19% 
37% 15% 
19% 
7% 
3% 
Totally disagree   
Disagree 
Rather disagree 
Neither disagree or 
orούτε agree 
Rather agree 
Agree 
 
 
From 149 people asked the majority –71% - disagreed with the statement with 
the statement that Medical Representatives that visit them blame others for their 
mistakes.  
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MR that visit me usually don’t give accurate data about the side 
effects of the drugs 
10% 
22% 
23% 
18% 
16% 
9% 
1% 1% 
DK/NA 
Totally disagree 
Disagree 
Rather disagree 
Neither disagree 
or agree 
Rather agree 
Agree 
Totally agree 
 
 
From 149 people asked the majority –55% - did not agree with the statement 
that Medical Representatives usually do not give accurate data about the side 
effects of the drugs. 
 
 
The MR that visit me usually do not do me favors so to feel  
obliged towards them 
1% 5% 
10% 
22% 
28% 
14% 
17% 
3% NK/NA 
Totally disagree   
Disagree 
Rather disagree 
Neither disagree 
or agree 
Rather agree  
Agree 
Totally agree 
 
 
From 149 people asked the majority –37% - disagreed with the statement that 
Medical Representatives that visit them usually don‟t do them favors in order to 
make them feel obliged towards them. 
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MR that visit me often promote drugs with a likelihood of 
increased side effects 
1
% 
12
% 
33
% 
19
% 
19
% 
13
% 
3
% 
DK/NA 
Totally disagree  
Disagree 
.Rather 
disagree 
Neither disagree 
or agree 
Rather agree 
Agree 
 
 
From 149 people asked the majority - 64% - disagreed that Medical 
Representatives promote drugs with who may have increased side effects. 
 
 
MR that visit me usually exaggerate when presenting the 
benefits of a new drug 
1% 
3% 
6% 
11
% 
12
% 
31
% 
28
% 
8% 
DK/NA 
Totally disagree   
Disagree 
Rather disagree 
Neither disagree 
or agree 
Rather agree 
Agree 
Totally agree 
 
 
From 149 people asked, the majority -67% - agrees with the statement that 
Medical Representatives usually exaggerate when presenting the benefits of a 
new drug.  
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MR that visit me usually are not compeletely honest as for 
the sufficiency of quantities of drugs in the market 
1% 
7% 
30% 
15% 
27% 
10% 
8% 
2% 
DK/NA 
Totally disagree 
Disagree 
Rather disagree 
Neither disagree or 
agree 
Rather agree 
Agree 
Totally agree 
 
 
From 149 people asked, the majority –52%- disagreed with the statement that 
Medical Representatives that visit them usually are not completely honest as for 
the sufficiency of the quantities of some drugs in the market.  
 
 
MR that visit me usually make bad remarks about their 
competition 
17
% 
22
% 
15
% 
21
% 
17
% 
5% 3% 
Totally disagree 
Disagree 
Rather disagree 
Neither disagree or 
agree 
Rather agree 
Agree 
Totally agree 
 
 
From 149 people asked, the majority - 54% - disagreed with the statement that 
Medical Representatives that visit them usually make negative comments for 
their competition.  
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MR that visit me usually are interested only for their own interests 
and not mine 
1% 5% 
21% 
17% 
29% 
15% 
9% 
3% 
DK/NA 
Totally disagree 
Disagree 
Rather disagree 
Neither agree 
or disagree 
Rather agree 
Agree 
Totally agree 
 
 
From 149 people asked the majority - 43% - disagreed that Medical 
Representatives are usually only interested in their own interests and not theirs.  
 
 
 
MR that visit me when asked usually reply even though they are 
not familiar with the topic 
11% 
29% 
18% 
13% 
17% 
11% 
1% 
Totally disagree 
Disagree 
Rather disagree 
Neither disagree or agree 
Rather agree 
Agree 
Totally agree 
 
From 149 people asked the majority –58% - disagreed with the statement that 
Medical Representatives that visit them usually reply even when not familiar with 
the topic.  
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MR that visit me often give misleading information in case 
their competition is present 
1
% 18
% 
32
% 
15
% 
24
% 
5
% 
4
% 
1
% 
NK/NA 
Totally 
disagree 
Disagre
e 
Rather 
disagree 
Neither disagree  
or agree 
Rather agree 
Agree 
Totally agree 
 
 
From 149 people asked the majority–65% - did not agree with the statement 
that Medical Representatives that visit them give misleading information in case 
their competition is present during the visit.  
 
 
MR that visit me are usually pressuring me in order to 
ensure prescriptio  of their drugs 
4% 
17% 
17% 
16% 
25% 
17% 
4% Totally disagree 
Disagree 
Rather disagree 
Neither disagree 
or agree 
Rather agree 
Agree 
Totally agree 
 
 
From 149 people asked the majority -46%- agreed that with the statement that 
Medical Representatives that visit them are usually very persuasive in order to 
ensure prescribing of the drugs they promote.  
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MR that visit me often make suggestions that contradict to the Code of Ethics 
of pharmaceutical companies 
1% 
24% 
33% 
13% 
20% 
5% 
2% 
2% 
DK/NA 
Totally agree 
Disagree 
Rather disagree 
Neither agree or 
disagree 
Rather agree 
Agree 
Totally agreee 
 
 
From 149 people asked, the majority -70%- disagreed that Medical 
Representatives disagreed with the statement that Medical Representatives that 
visit them often make suggestions that are not in line with the Code of Ethics of 
the pharmaceutical companies.  
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The following analysis describes the cooperation and relationship of 
Medical Representatives with the doctors as well as the quality of the 
visits they accept 
 
 
I consider MR useful partners 
 
1% 
1% 
1% 
4% 
5% 
26% 
42% 
20% 
DK/NA 
Totally disagree 
Disagree 
Rather disagree 
Neither disagree or 
disagree 
Rather agree 
Agree 
Totally agree 
 
 
From 149 people asked -88%- agreed that Medical Representatives are useful 
partners.   
 
 
Generally speaking how would you characterize your 
relationship with the MR that visit you? 
1% 
11% 
1% 
6% 
15% 
37% 
29% 
DK/NA 
Very bad 
Rather bad 
Neutral 
Rather good 
Good   
Very good 
 
 
From 149 people asked, the majority –52% - characterized as good their 
relationship with the Medical Representatives that visit them.  
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How would you characterize MR calls (visits)? 
1% 
1% 
1% 
5% 
38% 
41% 
13% Very bad 
Bad 
Rather bad 
Neutral 
Rather good 
Good   
Very good 
 
 
From 149 people asked the–92% -characterize as positive Medical 
Representative‟s calls 
 
4.2 Comparison of research findings with the aims of the assignment  
 
Based on the study‟s aim the following conclusion are drawn: 
The primary goal of this assignment was the research of the relative effect of the 
Medical Representatives in building company image, as well as investigating 
doctor‟s perception of Medical Representatives. Based on the theoretical models 
of Fobrun (1990) and Stewart (2004) that where presented, the parameters that 
are critical for defining company identity and the importance of Medical 
Representatives in building it, where identified. What is more, the three most 
important factors that impact doctor‟s perception (morality, trust and honesty) 
were evaluated.  
In order to further understand the function of pharmaceutical companies as well 
as the pharmaceutical market, there was a presentation of the pharmaceutical 
company the author works for as well as an analysis of the political, financial, 
structural and competitive environment of pharmaceutical market. 
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Each study must be supported by bibliography and scientific data, in order for its 
arguments to be established. 
The review of theoretical data was a major goal of this assignment. For the 
reasons mentioned before there was a large analysis of as many as possible 
theoretical approaches about company reputation with many data from 
international bibliography. At this point, company reputation was identified as an 
important company immaterial asset.  
 In the methodology chapter the basic research methods were indicated. 
These methods are mentioned in the bibliography as well as n the primary 
research method used. 
 The analysis of the research findings provided clear evidence about the 
perception of doctors for a company‟s image based on their perception of 
Medical Representatives.  
 Finally in the conclusions chapter there was an analysis of the elements 
pharmaceutical companies must focus on in order to improve its image 
and as a consequence its reputation.  
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CHAPTER 5 CONCLUSIONS, SUGGESTIONS 
 
5.1 Conclusion 
 
Medical information is at the moment the most accurate and at the same time 
expensive way for the pharmaceutical companies to communicate with their 
most important clients, the doctors. It has been proven that Medical 
Representatives are considered to be the third in importance characteristic 
element of a pharmaceutical company and there is a large extent of association 
of company identity and the identity of the sales force. Some of the largest 
pharmaceutical companies are ranked based on their company image, the 
performance of their sales force and their other capacities as perceived by the 
doctors. 
Handling company reputation from pharmaceutical companies is a multilevel fight 
in an extremely competitive environment. A positive company reputation is a 
priceless asset for every company because it offers a viable competitive 
advantage. From the targets set by pharmaceutical companies the major is the 
development of new products so as to increase market share. The second most 
pursued target is the increase in marketed products in existing markets and the 
least of these targets is the expansion in new markets abroad.  
In order to achieve these targets a series of strategic moves are being 
considered and used. These moves have to do with production, development, 
handling immaterial corporate assets and more specifically attracting, 
maintaining, developing and promoting employees through creating an attractive 
working environment and organizational flexibility for the company.  
After analyzing the findings of the primary research we reached to the following 
conclusions for Medical Representatives as a factor of creating company image in 
the Pharmaceutical Market and to the doctors. 
 For the total of the participating doctors and having as trust as a basic 
criterion, the biggest percentage (about 75%) agreed that indeed they 
trust the Medical Representatives when they visit them, basing their trust 
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on credibility and honesty, with no false statements and with the main 
target of the visit to be serving doctor‟s interests aiming at the benefit of 
the patients.  
 In the second level of questions and having as a primary topic Moral 
behavior of Medical Representatives the biggest percentage (76%) of 
participants agreed that the Medical Representatives show moral behavior, 
which means they do not alter scientific facts, provide accurate 
information about side effects of drugs, do not promote drugs with 
increased probability of side effects and do not exaggerate about the 
benefits of their products, don‟t make unethical remarks about their 
competition, retain a high business level, avoid giving vague information 
for matters they don‟t know, are very persistent when asking for 
prescriptions and don‟t do favors, so that the doctors will feel obligated 
towards them and last but not least not make suggestions that are against 
the Code of Ethics. 
 In the final level of questions that was researched, the usefulness of 
doctors cooperation with Medical Representatives the majority of the 
doctors (88%) agreed that Medical Representatives are useful partners for 
them, having built at the same time good, interpersonal and business 
relationships with them, (total percent 81%), basing their answers on the 
good visits, total percent of answers 92%   
Special emphasis should be given to the long-term persistence of 
pharmaceutical companies to hiring people with diplomas from Universities 
related to health studies in order to better serve the Medical community. 
Large amounts are invested for this and there is also a high cost of scientific 
training. By investing in this sort of training pharmaceutical companies wish 
to offer Medical Representatives an extensive scientific knowledge, not only 
for the drugs they represent, but also for the therapeutic areas these drugs 
are a part of so as to: 
 Fully understand the complicated mechanism of action of the drugs, even 
in patients that have co morbidity with other medical conditions  
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 Have such a high scientific level of knowledge so to make brief but 
complete informing statements about the drugs and be able to back up 
their arguments with solid scientific facts  
 Be able to answer all questions but also be able to make interesting 
questions about doctor‟s clinical experience or alternative treatment 
therapies that minimize the chances of adverse events emerging.  
As a conclusion Medical Representatives offer doctors new and important 
information so that doctors think of them as useful partners and accept their 
scientific value.  
Medical Representatives don‟t sell, but offer priceless information services and 
for that they must have all the necessary scientific reports and training, so as to 
transmit knowledge and be a part of the success for their company. Medical 
information requires interpersonal contact as part of the transactional 
communication. So the need for transmitting knowledge caused the need for the 
profession of Medical Representatives. And it is this need that will retain it in the 
changing environment of pharmaceutical market. 
Therefore much attention must be given when shaping the characteristics, 
attitude and qualities of sales force. They are a determinant factor of building a 
positive, strong company image. 
 
5.2 Direction for further research 
 
As noted earlier every study must be focused on its aims and targets. However, 
as the research proceeds and as bibliography is being reviewed, new areas for 
further research and evaluation emerge, areas that decamp from the primary 
aim of the study. 
The focus of the study was to present the facts and conditions of the 
pharmaceutical market. However, the same facts and conditions are valid not 
only for Greece, but also for Europe and worldwide. Governments are placing 
pressure on decreases in health expenditures, due to the fact that this has little 
political cost, while there is information that pharmaceutical companies result 
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with huge profits and therefore can reduce prices. Financial decline will lead to 
even more demanding customers who will ask for even cheaper drugs.  
Adding to the rest,  insurance organizations and hospitals, major customers of 
drugs, demand bigger participation in the decisions for drug use and finance.  
The basic function of Medical Representatives (sharing information with the 
doctors, reinforcing relationships with them and influencing their prescribing 
attitude) could be distributed to other channels. Doctors seem to strengthen their 
relationships with other customer elements (directors, hospital and other 
organizations executives, etc) and they will affect how doctors see 
pharmaceutical companies. Some doctors will no longer be interested in 
contacting with Medical Representatives but will prefer to use technological 
means to contact the pharmaceutical company. Moreover, there may be doctors 
that will make it impossible for building a relationship through Medical 
Representatives visits. 
A recent research in the USA that was completed in February 2005 showed that 
55% of doctors will provide Medical Representatives even fewer time and only 
3% will increase it. Also, Pan European researches show that the next 5 to 10 
years the major Decision Maker of drug policy will be insurance organizations 
and hospitals.  
The issues raised from the above facts are: 
 If someone else decides, should I continue to visit the doctor?  
 What will be the new role of Medical Representatives in order to be 
useful?  
 What will be the attitude and dealing of the emerging problems from the 
pharmaceutical companies towards the Medical Representatives?  
 What must be the characteristics of the modern Medical Representative?; 
 How strategic is Medical Representative today? Comparative data are not 
defined by him and at the same time he is part of a situation where 
strategy is defined by the company.  
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 Must companies show social responsibility? Should business social 
responsibility be related to financial politics of the pharmaceutical 
companies?  
 How do pharmaceutical companies executives feel about the environment 
that constantly changes and transforms in the drug market?  
The proportion that used to exist between the increase of Medical 
Representatives and sales is no longer valid. Sales are beginning to reach their 
higher limit and that generates thoughts and questions if the profitability of the 
sales departments is indeed the one expected. After the implementation of the 
Code of Ethics the environment is changing.   
Even though pharmaceutical companies are dealing with a lot of challenges there 
is good news too, mostly about the fact that the efficiency of the sales force is 
no longer a result of Medical Representative‟s productivity. On the contrary, 
efficiency starts from clinical trials and can reach to preparing a successful 
launch. On the other hand it is supported by the Continuing Medical Education 
(CME) of doctors, technological support teams, etc. The background for future 
success in sales and customer loyalty are based on CME and communication 
centers. For this reason the scenario that must be considered as a future factor 
for success is: higher performance with smaller sales teams. 
We must also point out that Medical Representatives are the foundation of all 
successful companies, not only in Greece, but also in Europe and the USA. Also, 
it is one of the most expensive investments. However strange it may seem the 
mean cost of a medical representative, including bonus, car, etc is more than 
€60.000 and this is little compared to UK or USA, where the cost is more than 
€120.000. Moreover, when a medical representative leaves this costs the 
company about €185.000, which includes the hiring and training cost and the 
lost productivity time.  
So there is much talk about where the productivity of the sales force is still highly 
related to training, values and the companies vision.  
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Questionnaire 
 
Hello. My name is Athanasios Pastogiannis. I work in the pharmaceutical 
company Pfizer Hellas and I am the District Manager of CNS. Parallel to my work 
I do an MBA in Iternational Hellenic University. We are conducting a research 
with another student, Christos Dionysatos, for the medical representatives and 
how they are a factor of building company reputation. Also the research focuses 
on how doctor‟s perception of medical representatives and a pharmaceutical 
company shapes. 
Bellow you will find a questionnaire that would really help if you could take some 
time and fill it out. In this way we will collect data that will help our research. 
Your contribution to our assignment will help its success. 
We would like to thank you in advance and guarantee the confidentiality of your 
answers. The questionnaire is anonymous. Please answer all questions with 
honesty and after some though.  
 
Thank you for your cooperation. 
Yours truly, 
Athanasios Pastogiannis 
Christos Dioniysatos 
 
 
Questionnaire  
 
Dear Doctor, 
The questionnaire aims at evaluating the importance of the Medical 
Representative‟s Team in shaping a company image, as well as your perception 
for Medical Representatives of Pharmaceutical Companies.  
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Demographic information  
 
  Pathology  Νeurology  Psychiat
ry 
  
Speciality        
 
 
         
  Private 
office 
      Public  Private 
clinic 
  
           Place or 
work 
        
         
How much do you agree or disagree with each of the following phrases:  
(Cycle a number for each answer according to the following scale) 
1.Totaly disagree  2.Disagree 3. Rather disagree 4. Neither agree or disagree 
5. Rather agree 6. Agree  7. Totally agree 
 
1.1 The Medical Representatives that visit me are usually honest  1 2 3 4 5 6 7 
1.2 The Medical Representatives that visit me don‟t lie  1 2 3 4 5 6 7 
1.3 The Medical Representatives that visit me are not totally honest 
when informing me 
1 2 3 4 5 6 7 
1.4 The Medical Representatives that visit me are mostly interested 
in serving their interests  
1 2 3 4 5 6 7 
1.5 The Medical Representatives that visit me don‟t seem to care 
about my needs  
1 2 3 4 5 6 7 
1.6 My partners don‟t usually trust Medical Representatives  1 2 3 4 5 6 7 
1.7 The Medical Representatives that visit me are usually unreliable  1 2 3 4 5 6 7 
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2.1 The Medical Representatives that visit me often misrepresent 
scientific data about drugs  
1 2 3 4 5 6 7 
2.2 The Medical Representatives that visit me often blame others for 
their mistakes  
1 2 3 4 5 6 7 
2.3 The Medical Representatives that visit me usually don‟t give 
accurate data about the side effects of drugs 
1 2 3 4 5 6 7 
2.4 The Medical Representatives that visit me usually take advantage 
of new and inexperienced doctors  
1 2 3 4 5 6 7 
2.5 The Medical Representatives that visit me usually don‟t do me 
favors so to feel obliged towards them  
1 2 3 4 5 6 7 
2.6 The Medical Representatives that visit me often promote drugs 
with a likelihood of increased side effects  
1 2 3 4 5 6 7 
2.7 The Medical Representatives that visit me usually exaggerate 
when presenting the benefits of a new drug 
1 2 3 4 5 6 7 
2.8 The Medical Representatives that visit me usually are not 
completely honest as for the sufficiency of quantities of drugs in 
the market  
1 2 3 4 5 6 7 
2.9 The Medical Representatives that visit me usually make bad 
remarks about their competition 
1 2 3 4 5 6 7 
2.10 The Medical Representatives that visit me usually are interested 
only for their own interests and not mine  
1 2 3 4 5 6 7 
2.11 The Medical Representatives that visit me when asked usually 
reply even though they are not well familiar with the topic  
1 2 3 4 5 6 7 
2.12 The Medical Representatives that visit me often give misleading 
information in case their competition is present  
1 2 3 4 5 6 7 
2.13 The Medical Representatives that visit me are usually pressuring 
me in order to ensure the prescription of their  
1 2 3 4 5 6 7 
2.14 The Medical Representatives that visit me often make 
suggestions that contradict to the Code of Ethics of 
1 2 3 4 5 6 7 
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pharmaceutical companies  
 
How much do you agree or disagree with the phrase bellow that 
concerns your collaboration with the Medical Representatives of 
pharmaceutical companies that visit you? 
3.1 I consider the Medical Representatives useful partners  1 2 3 4 5 6 7 
 
 
3.2. Generally speaking how would you characterize your relationship with the 
Medical Representatives that visit you?  
 (Cycle a number in every answer according to the following scale) 
 1. Very bad 2. Bad 3. I think bad 4. Neutral 5. I think good  
6. Good  7. Very good 
1 2 3 4 5 6 7 
         
3.3 How would you characterize the calls of Medical 
Representatives? 
       
 (Cycle a number in every answer according to the following scale) 
 1. Very annoying 2. Annoying 3. I think annoying 4. With no 
interest  
5. I think useful 6. Useful 7. Very useful 
1 2 3 4 5 6 7 
 
 
 
  Athens  Patras  Heralkeion  Ioannina 
4. Area of work         
         
  Less than 
10 
 10-15  More than 
15 
  
 60 
 
5. How many years 
have you been 
practicing this 
medical 
profession? 
  
 
      
 
 
        
  YES  NO     
6. Have you 
practiced medicine 
abroad? 
        
 
     Bellow 40      41-55       55-
60 
   Over 60 
             Age        
 
 
 
 
        
   Male    Fenale     
            Sex        
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Results of the study 
 
Results of primary reserach 
All analysis was conducted using the statistical program SPSS 13 (Statistical Package for 
Social Sciences). This program has the ability to manage a vast volume of data and 
perform complicated calculations.  
 
Results and analysis 
The sample of the research will be described first, by analyzing the specialty of the 
participants, the place of work and the work area, the years they have been practicing the 
medical profession and whether they have practiced it abroad, as well as the gender and 
the age of the participants. 
 
Specialty 
1% 3% 
32% 
64% 
DK/NA 
Path 
Neurol 
Psych 
 
From 149 people asked, 96 where psychiatrists and represent 64,4% of the total, 48 where 
neurologists and represent 32,2% of the total, 4 represent 2,7% of the total and 1% did 
not answer.  
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Place 
7% 
48% 
44% 
1% DK/N
A 
PrOffice 
Public 
PrClinic 
 
From 149 people asked, 72 work in a private office and represent 48,3% of the total, 65 
work in public hospitals etc and represent 43,6% of the total, 2 work in private clinics and 
are 1,3% of the total and 10 did not answer.  
 
 
 
Work area 
1% 
78% 
11% 
5% 5% 
NK/NA Athens Patra Heraklion Ioannina 
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From 149 people asked 116 work in Athens and represent 77,9% of the total, 16 work in 
Patra and represent 10,7% of total, 8 work in Heraklion and represent 5,4% of total, 8 
work in Ioannina and represent 5,4% of total and 1 did not answer.  
 
From 149 people asked 71 have been practicing more than 15 years and represent 47,7% 
of the total, 38 have been practicing for 10-15 years and represent 25,5% of the total, 40 
have been practicing less than 10 years and represent 26,8% of the total.  
 
 
 
Years of practice 
27% 
26% 
47% 
Less than 10 10-15 . More than 15 
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Ηave you practiced medicine 
abroad? 
30% 
70% 
Yesι No 
 
From 149 people asked 105 have not practiced medicine abroad and represent 70,5% of 
the total, while 44 have practiced medicine abroad and represent 29,5% of the total. 
 
 
From 149 people asked 81 are 41-55 years old and represent 54,4% of the total, 48 are 
bellow 40 and represent 32,2% of the total, 11 are 55-60 year sold and represent 7,4% of 
the total and 9 are above 60 and represent 6% of the total. 
 
 
Age 
32% 
55% 
7% 6% 
Bellow 40 
41-55. 
55-60. 
Above 60 
 65 
 
 
 
From 149 people asked 95 are men and represent 63,8% and 54 are women and represent 
36,2% of the total. 
Gender 
64% 
36% 
Άντρας 
Γσναίκα 
